The company has assembled an alcohol-free sanitisation travel retail exclusive pack for Nilaqua, a firm that produces waterless hygiene products such as shampoo and handwash and is a major supplier to the NHS. GMAX Travel Retail has also teamed up with PPE Solutions in Ireland.
In an Adapt & Survive interview, GMAX Travel Retail Founder Garry Maxwell touches on the importance of ensuring product certifications and test reports for PPE products.
The segment has proliferated since the Covid-19 crisis began, but reports of fake products, unscrupulous manufacturers and dubious procurement standards have been rife in recent months.
Maxwell discusses the challenges of supplying PPE products to buyers not typically used to purchasing goods of this nature and distributing them in large quantities to those organisations and governments around the world that require them.
The GMAX Travel Retail proprietor, an experienced and popular figure in the industry, left Premier Portfolio International at the end of last month.
He was a stalwart at the company owned by Kevin Walsh and Andrew Webster, having served the inflight retail specialist for nearly two decades.
The erstwhile Sales Director continues to be responsible for Premier’s logoed merchandise, which includes the highly successful ‘Fun Plane’ toy range and scalable aircraft models, alongside his new responsibilities at GMAX Travel Retail.
The current GMAX Travel Retail product portfolio also includes beauty brand Transformulas, wellbeing brand eyeSlices and Beauty Blvd.
GMAX Travel Retail is also in discussion with a men’s grooming brand and is working with an electronics company.
The TRBusiness ‘Adapt and Survive’ Skype video interview series is a direct response to the industry’s critical need for direct, factual and analytical commentary and – in typical TRBusiness fashion – interprets clearly and concisely the challenges faced by travel retail during Covid-19.
Adapt & Survive asks members of the travel retail industry community, often working from home, for their candid commentary on the constantly evolving Covid-19 pandemic.